Edwards Lifesciences Q1 FY26: where the revenue came from and where it went
The whole income statement of Edwards Lifesciences for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jan 1 – Mar 31, 2026
- Reported
- May 6, 2026
Revenue$1.65B
+17% year over year
Gross profit$1.29B
78% margin
Operating profit$0.48B
29% margin
Net profit$0.38B
23% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 1.65 | 100% | +17% |
| Aortic valve replacement | 1.20 | 72% | +14% |
| Surgical | 0.28 | 17% | +10% |
| Transcatheter mitral | 0.18 | 11% | +52% |
| Cost of revenue | −0.36 | 22% | |
| Gross profit | 1.29 | 78% margin | −1pp |
| R&D | −0.26 | 16% | −2pp |
| SG&A | −0.52 | 32% | −1pp |
| Other | −0.02 | 1% | +0pp |
| Operating profit | 0.48 | 29% margin | +1pp |
| Interest & other costs | −0.02 | ||
| Tax | −0.08 | ||
| Net profit | 0.38 | 23% margin | −2pp |
154 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest